MUTATIONAL LANDSCAPE OF RELAPSED ACUTE PROMYELOCYTIC LEUKEMIA

EHA Learning Center, Valentina Alfonso, 214635

THE ROLE OF THE TRANSCRIPTION FACTOR GFI1 IN LEUKEMIA GENOME STABILITY AND EVOLUTION

EHA Learning Center, Daria Frank, 214636

VEGFC ANTIBODY TREATMENT: A NEW DIFFERENTIATION THERAPY FOR AML

EHA Learning Center, Kim Kampen, 214637

IMPACT OF NPM1 MRD STATUS AFTER TWO CYCLES OF INTENSIVE CHEMOTHERAPY TO INFORM TYPE OF POST-REMISSION THERAPY: A STUDY OF THE AML STUDY GROUP (AMLSG)

EHA Learning Center, Silke Kapp-Schwoerer, 214651

DISTINCT DNA METHYLATION PROFILES IN DIFFERENT CYTOGENETIC SUBGROUPS OF CHRONIC LYMPHOCYTIC LEUKEMIA: THE INTRIGUING CASE OF TRISOMY 12

EHA Learning Center, MARIA TSAGIOPOULOU, 214652

BIALLELIC INACTIVATION OF ATM AND BIRC3 IN DEL(11Q) CELLS DRIVES GENOMIC INSTABILITY AND TUMOR EXPANSION IN CRISPR/CAS9-GENERATED MODELS OF CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Learning Center, Miguel Quijada Alamo, 214653

TITLE: PROGNOSTIC IMPACT OF THE BCR/ABL1-LIKE SIGNATURE IN ADULT B-LINEAGE ALL. FIRST ANALYSIS OF THE GIMEMA LAL1913 PROTOCOL

EHA Learning Center, Sabina Chiaretti, 215235

CHARACTERIZATION OF PEDIATRIC T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH DNA METHYLATION STATUS

EHA Learning Center, Shunsuke Kimura, 215236

THE PHILADELPHIA-LIKE SUBTYPE IN CHILDREN WITH FIRST RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: A STUDY OF THE GERMAN ALL-REZ BFM 2002 TRIAL

EHA Learning Center, Malwine Pogodzinski, 215237

LOW MIR-151 AND MIR-451 LEVELS IN BONE MARROW AT DIAGNOSIS IS CONFIRMED AS A PROGNOSTIC FACTOR FOR RELAPSE OF B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM THE AIEOP 2000 CLINICAL TRIAL

EHA Learning Center, Jennifer Yarden, 215252

THE CELL SURFACE PROTEIN VANIN-2 IDENTIFIES AGGRESSIVE SUBTYPES OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Learning Center, Virginia Rodriguez Martinez, 215253

NILOTINIB COMBINED WITH LOWER-INTENSITY CHEMOTHERAPY FOR FRONT-LINE TREATMENT OF YOUNGER ADULTS WITH PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): INTERIM ANALYSIS OF THE GRAAPH-2014 TRIAL

EHA Learning Center, Yves Chalandon, 215254

FLT3-ITD ANALYSIS ON RNA CONFERS ENHANCED SENSITIVITY AND ALLOWS EARLIER RELAPSE PREDICTION

EHA Learning Center, Elisabeth Oppliger Leibundgut, 215269

PHARMACOLOGIC INHIBITION OF CELLULAR METABOLIC PROCESSES IMPACTED BY AGING SENSITIZE ACUTE MYELOID LEUKEMIA (AML) CELLS TO THE NOVEL LIPOATE DERIVATIVE CPI-613

EHA Learning Center, Timothy Pardee, 215270

GENOMIC CHARACTERIZATION OF DIAGNOSTIC AND REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA SAMPLES THROUGH A NEXT GENERATION SEQUENCING (NGS) PANEL OF 62 GENES

EHA Learning Center, Diego Carbonell, 215271

GENOMIC-DRIVEN AND FUNCTIONAL ALTERATIONS IN ENERGY, AMINO ACID AND LIPID METABOLISM IN ACUTE MYELOID LEUKEMIA BLASTS AND STEM PROGENITOR CELLS

EHA Learning Center, Giorgia Simonetti, 215285

THE CALCIUM BINDING PROTEIN S100A8/S100A9 COMPLEX IS ASSOCIATED WITH DRUG RESISTANCE IN ACUTE MYELOID LEUKEMIA

EHA Learning Center, Riikka Karjalainen, 215286

A HIGH RISK PEDIATRIC AML SUBTYPE PRESENTS A DIAGNOSTIC CHALLENGE-A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP AAML0531 STUDY

EHA Learning Center, Timothy P Singleton, 215288

EVALUATION OF THE DRUG INTERACTION POTENTIAL OF PRACINOSTAT, A NOVEL HISTONE DEACETYLASE (HDAC) INHIBITOR, WITH CYP1A2 INDUCER CIGARETTE SMOKING AND CIPROFLOXACIN, A CYP1A2 INHIBITOR

EHA Learning Center, Alberto Bernareggi, 215302

SINGLE CENTRE REAL-LIFE EXPERIENCE OF HYPOMETHYLATING AGENTS WITH OR WITHOUT DLI AS SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA RELAPSING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.

EHA Learning Center, Davide Lazzarotto, 215303

CONSOLIDATION CHEMOTHERAPY PREVENTS RELAPSE BY INDIRECTLY REGULATING BONE MARROW ADIPOGENESIS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Learning Center, Hanyan Liu, 215304

CELL-FREE DNA MONITORING OF MINIMAL RESIDUAL DISEASE IN AML USING A TARGETED NGS GENE PANEL

EHA Learning Center, Zhiyi Xie, 215318

INTRA-PATIENT DOSE-ESCALATION STUDY OF CRENOLANIB MAINTENANCE THERAPY IN PATIENTS WITH FLT3 MUTANT AML WHO HAD UNDERGONE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT)

EHA Learning Center, Betul Oran, 215319

CONSOLIDATION THERAPY WITH PONATINIB IN COMBINATION WITH CYTARABINE IN PATIENTS FOR FLT3-ITD ACUTE MYELOID LEUKEMIA IN FIRST COMPLETE REMISSION.

EHA Learning Center, Philippe Rousselot, 215320

BIOMARKER ANALYSIS OF TISAGENLECLEUCEL PRE-INFUSION BIOPSIES OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

EHA Learning Center, Ulrich Jäger, 215334

ACALABRUTINIB IN COMBINATION WITH THE PI3Kδ INHIBITOR ACP-319 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES.

EHA Learning Center, Paul M. Barr, 215335

TIME TO RELAPSE OF MANTLE CELL LYMPHOMA AFTER INTENSIVE HIGH DOSE CYTARABINE CONTAINING REGIMENS DEFINES PATIENTS RISK FOR DEATH: AN ANALYSIS FROM CENTERS OF THE FONDAZIONE ITALIANA LINFOMI

EHA Learning Center, Carlo Visco, 215336

ON THE APPLICABILITY OF RHOA GLY17VAL POINT MUTATION TESTING FOR A DIFFERENTIAL DIAGNOSIS OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA

EHA Learning Center, Yulia Sidorova, 215350

THE ADDITION OF ROMIDEPSIN TO CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IS FEASIBLE IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS: RESULTS OF PHASE IB FIL-PTCL13

EHA Learning Center, Annalisa Chiappella, 215351

A PHASE I, MULTICENTER, OPEN-LABEL DOSE-ESCALATION STUDY OF CC-122, A NOVEL CEREBLON-MODULATING AGENT, IN ADULT JAPANESE PATIENTS WITH ADVANCED NON-HODGKIN LYMPHOMA OR SOLID TUMOR

EHA Learning Center, Kazuhito Yamamoto, 215352

HAEMOSTATIC ABNORMALITIES OR DEFECTS IN GREEK PATIENTS WITH GAUCHER DISEASE

EHA Learning Center, Veroniki Komninaka, 215366

THALIDOMIDE USE IN HEREDITARY HEMORRHAGIC TELANGIECTASIA: A RETROSPECTIVE EVALUATION OF THE PATIENTS

EHA Learning Center, Mehmet Baysal, 215367

ADULT PATIENTS WITH ACQUIRED PURE RED CELL APLASIA: COMBINATION OF CYCLOSPORINE A AND CORTICOSTEROIDS PRODUCE BETTER CR

EHA Learning Center, Guangsheng He, 215382

MANAGEMENT OF PATIENTS WITH SEVERE APLASTIC ANAEMIA WHO ARE REFRACTORY TO PLATELET TRANSFUSIONS USING LEUKOCYTE CONCENTRATES

EHA Learning Center, jiali Huo, 215383

ILT3/DELTEX-1/SHIP-1 AS A NOVEL INHIBITORY AXIS CONTROLLING B CELL RECEPTOR SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Learning Center, Anna Kabanova, 215399

DETIN: OVERCOMING TUMOR IN NORMAL CONTAMINATION.

EHA Learning Center, Amaro Taylor-Weiner, 215400

“IMMUNO-FLOW-FISH”: HIGH THROUGHPUT FLUORESCENCE IN SITU HYBRIDISATION OF PHENOTYPED CHRONIC LYMPHOCYTIC LEUKAEMIA BY IMAGING FLOW CYTOMETRY FOR CLINICAL APPLICATION

EHA Learning Center, Wendy Erber, 215415

EXPRESSION OF ANTIGENS INVOLVED IN THE FORMATION OF AN IMMUNOLOGICAL SYNAPSE IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Learning Center, Yulia Davydova, 215416

FREQUENCY OF TYPICAL AND ATYPICAL FUSION TRANSCRIPTS IN PATIENTS WITH BCR-ABL1-POSITIVE LEUKEMIAS – A SINGLE INSTITUTION STUDY

EHA Learning Center, Gueorgui Balatzenko, 215431

PATIENT-SPECIFIC BCR-ABL1 GENOMIC FUSION ANALYSIS OF MINIMAL RESIDUAL DISEASE OF CML PATIENTS ELIGIBLE FOR TKI STOPPING SIGNIFICANTLY OUTPERFORMED MRNA DETECTION EITHER BY QPCR OR DIGITAL PCR

EHA Learning Center, Katerina Machova Polakova, 215432

LONG-TERM TREATMENT RESPONSE BASED ON SEVERITY OF GAUCHER DISEASE TYPE 1 AT BASELINE IN TREATMENT-NAÏVE ADULT PATIENTS AFTER 8 YEARS OF TREATMENT WITH ORAL ELIGLUSTAT

EHA Learning Center, Elena Lukina, 215448

COMBINED EMA-BINDING TEST AND OSMOTIC GRADIANT EKTACYTOMETRY SIGNIFICANTLY IMPROVE THE LABORATORY DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS

EHA Learning Center, Andreas Glenthøj, 215449

SIGNIFICANT ARI-0001 (A3B1:CD8:4-1BB:CD3Z CAR19) CELL EXPANSION IN A PATIENT WITH REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA THROUGH PRE-LYMPHOAPHERESIS IBRUTINIB ADMINISTRATION.

EHA Learning Center, Valentín Ortiz-Maldonado Gibson, 215464

HIGH BASELINE FERRITIN IS ASSOCIATED WITH GRADE 2 CRS REQUIRING TOCILIZUMAB OR GRADE ≥ 3 CRS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED WITH BB2121 ANTI-BCMA CAR T CELLS

EHA Learning Center, Jesus Berdeja, 215465

IMPACT OF SPLENECTOMY ON CD34+ BLOOD COUNT

EHA Learning Center, Irina Galtseva, 215480

VERY LATE RELAPSES (VLRS) IN HODGKIN LYMPHOMA (HL) OCCURING ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY ± RADIOTHERAPY (CT±RT): PATTERN OF RISK OVER 35 YEARS AND THE SIGNIFICANCE OF HISTOLOGY

EHA Learning Center, Theodoros Vassilakopoulos, 215481

OVERALL SURVIVAL OF MANTLE CELL LYMPHOMA (MCL) PATIENTS HAS BEEN SIGNIFICANTLY IMPROVED DURING THE TIME, MAINLY DUE TO THE RITUXIMAB MAINTENANCE IN ELDERLY POPULATION, REAL WORLD DATA.

EHA Learning Center, Marek Trneny, 215496

IBRUTINIB FOR THE TREATMENT OF BING-NEEL SYNDROME

EHA Learning Center, Jorge Castillo, 215497

TETANUS, DIPHTHERIA AND POLIO IMMUNITY AFTER CHEMOTHERAPY AND RITUXIMAB IN PATIENTS WITH LEUKEMIA AND LYMPHOMA

EHA Learning Center, Sigrun Einarsdottir, 215513

THE DIAGNOSTIC UTILITY AND SENSITIVITY OF THE XPERT® MTB/RIF ASSAY IN DIAGNOSING MYCOBACTERIUM TUBERCULOSIS IN BONE MARROW ASPIRATE SPECIMENS

EHA Learning Center, Nadhiya Subramony, 215514

ACERULOPLASMINAEMIA - THE EXTREMELY RARE ALSO EXISTS

EHA Learning Center, João Gomes, 215530

IT TAKES A LOT OF IRON TO AVOID TRANSFUSION

EHA Learning Center, Magda Jabbar Al-Obaidi, 215531

COMPLETE BLOOD COUNT- BASED SCORE FOR THE DIAGNOSIS AND PROGNOSIS OF MYELODYSPLASTIC SYNDROMES IN CYTOPENIC PATIENTS

EHA Learning Center, Marion Eveillard, 215546

AUTOPHAGY IN MYELODYSPLASTIC SYNDROMES: THE ROLE OF HIF-1A/REDD1 MOLECULAR PATHWAY

EHA Learning Center, Ioanna STERGIOU, 215547

SEVERE THROMBOCYTOPENIA AS A PREDICTOR OF SURVIVAL AND RESPONSE TO HYPOMETHYLATING AGENTS: DATA FROM A LATIN-AMERICAN COHORT

EHA Learning Center, Carolina Lazzarino, 215563

TLR4 SIGNALING DRIVES MESENCHYMAL STEM CELLS (MSC) COMMITMENT TO PROMOTE TUMOR MICROENVIRONMENT TRANSFORMATION IN MULTIPLE MYELOMA

EHA Learning Center, Cesarina Giallongo, 215564

JAGGED1/2 INHIBITION PROMOTES TUMOR CELLS RESPONSE TO BORTEZOMIB IN A ZEBRAFISH MODEL OF MULTIPLE MYELOMA

EHA Learning Center, Maria Teresa Palano, 215579

TGFΒ INHIBITION IN COMBINATION WITH CHEMOTHERAPY REPAIRS EXISTING LYTIC BONE LESIONS IN A NOVEL PLATEAU PHASE MODEL OF MULTIPLE MYELOMA

EHA Learning Center, Andrew Chantry, 215580

SKY92 RISK STRATIFICATION AT RELAPSE PROVIDES ADDITIONAL PROGNOSTIC INFORMATION FOR STANDARD-RISK MULTIPLE MYELOMA PATIENTS

EHA Learning Center, Rowan Kuiper, 215595

CARFILZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE IN TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PRELIMINARY RESULT OF SGHMM1 TRIAL, HIGH-RISK COHORT (NCT02217163)

EHA Learning Center, Chandramouli Nagarajan, 215596

SERIAL SERUM FREE LIGHT CHAIN ASSAY CAN REDUCE THE NEED FOR 24-HOUR URINE PROTEIN ASSESSMENT FOR RESPONSE ASSESSMENT IN MULTIPLE MYELOMA

EHA Learning Center, Marcella Tschautscher, 215611

NOVEL THERAPIES DIFFERENTIALLY IMPACT POLYCLONAL IMMUNOGLOBULIN RECOVERY IN MYELOMA PATIENTS: A LONGITUDINAL STUDY

EHA Learning Center, Mauricette Michallet, 215612

MULTIPLE MYELOMA IN PATIENTS UNDER 40 YEARS OLD: A RETROSPECTIVE ANALYSIS FROM THE INTERGOUPE FRANCOPHONE DU MYELOME (IFM).

EHA Learning Center, Alexis Caulier, 215627

AMPLICON NEXT-GENERATION SEQUENCING (NGS) OF REARRANGED IMMUNOGLOBULIN (IG) LOCI IS ADVANTAGEOUS FOR CLONAL MARKER IDENTIFICATION AND MINIMAL RESIDUAL DISEASE (MRD) DETECTION IN MULTIPLE MYELOMA (MM).

EHA Learning Center, Michaela Kotrová, 215628

BOARDING ON THE SECRETARY PATHWAY IS REQUIRED FOR THE ONCOGENIC PROPERTY OF MUTANT CALRETICULIN

EHA Learning Center, Marito Araki, 215643

PHARMACOLOGICAL INHIBITION OF IGF1R/IRS TARGETING STAT3/STAT5 SIGNALING HAS ANTI-NEOPLASTIC EFFECTS IN JAK2 V617F MYELOPROLIFERATIVE NEOPLASMS

EHA Learning Center, Jaqueline Cristina Fernandes, 215644

LIMITATIONS OF PREVIOUS PROGNOSTIC MODELS FOR THROMBOSIS AND EXPLORATION OF MODIFIED MODELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA

EHA Learning Center, Yoshinori Hashimoto, 215659

SERVICE EVALUATION OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM AND SPLANCHNIC VEIN THROMBOSIS (MPN-SVT).

EHA Learning Center, Sarah Wharin, 215660

SPLENIC MARGINAL ZONE B-CELL LYMPHOMAS DEPENDS ON PROGRAMMED DEATH-LIGAND 1 FOR CLONAL EMERGENCE AND ARE CONTROLLED BY T-CELLS FOR PROLIFERATION RATE

EHA Learning Center, Nathalie FAUMONT, 215676

MECHANISMS CONFERRING RESISTANCE TO VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA

EHA Learning Center, Daniela Steinbrecher, 215677

PREDICTIVE FACTORS FOR DEVELOPING SYSTEMIC LUPUS ERYTHEMATOSUS AFTER CHILDHOOD AUTOIMMUNE CYTOPENIA

EHA Learning Center, Nathalie Aladjidi, 215693

THE POLYMORPHISM OF CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 9 GENE MAY CONTRIBUTE TO RISK OF IMMUNE THROMBOCYTOPENIA

EHA Learning Center, Zi Sheng, 215694

THE IMPACT OF HIGH MOBILITY GROUP BOX 1 IN THE PATHOGENESIS OF IMMUNE THROMBOCYTOPENIA

EHA Learning Center, Mehmet Baysal, 215709

WHAT ARE THE UNDERLYING CAUSES AND CLINICAL CHARACTERISTICS OF CHILDREN WITH REACTIVE THROMBOCYTOSIS AT A KOREAN TERTIARY MEDICAL CENTER?

EHA Learning Center, Ye Jee Shim, 215710

VENETOCLAX IMPROVES QUALITY OF LIFE FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Learning Center, Tara Cochrane, 215726

NO ASSOCIATION BETWEEN INDOOR RADON AND CHILDHOOD LEUKEMIA IN FRECCLE (FINNISH REGISTER-BASED CASE-CONTROL STUDY OF CHILDHOOD LEUKEMIA)

EHA Learning Center, Atte Nikkilä, 215727

SICKLE CELL DISEASE SEVERITY MEASURE: DEVELOPMENT, TRANSLATION, AND PATIENT CULTURAL SENSITIVITY VALIDATION

EHA Learning Center, Kenneth Bridges, 215742

IMPROVEMENT OF THE MULTIDISCIPLINARY MANAGEMENT OF SICKLE CELL DISEASE PATIENTS: IMPLEMENTATION OF A SICKLE CELL DISEASE PATIENT’S CLINICAL DATABASE: BELGIAN REGISTER OF SICKLE CELL DISEASE PATIENTS

EHA Learning Center, Beatrice Gulbis, 215743

VARIATIONS IN COMPLICATIONS RELATED TO VASO-OCCLUSIVE CRISES AND HYDROXYUREA USE IN PATIENTS WITH SICKLE CELL DISEASE: OBSERVATIONS FROM STUDIES IN THE USA, SPAIN AND THE GULF REGION

EHA Learning Center, Elena Cela, 215744

BUSULFAN FLUDARABINE (BU-FLU) COMPARED TO THIOTEPA BUSULFAN FLUDARABINE (TBF) FOR ALLOGENEIC TRANSPLANTS IN ACUTE MYELOID LEUKEMIA (AML) OR REFRACTORY ANEMIA WITH EXCESS BLASTS (RAEB) IN REMISSION

EHA Learning Center, Andrea Bacigalupo, 215758

EFFICACY AND SAFETY OF DEFIBROTIDE BY VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) DIAGNOSTIC CRITERIA IN AN EXPANDED-ACCESS (T-IND) STUDY

EHA Learning Center, Selim Corbacioglu, 215759

PLASMA PRESEPSIN LEVEL IS A PREDICTIVE MARKER OF SEVERE ACUTE GVHD AFTER ALLO-HSCT: USEFULNESS AS A BIOMARKER OF ALLO-HSCT RELATED COMPLICATION

EHA Learning Center, Tatsuo Oyake, 215760

EARLY BLOOD STREAM INFECTION AFTER BMT IS ASSOCIATED WITH CYTOKINE DYSREGULATION AND POOR OVERALL SURVIVAL

EHA Learning Center, Kate Markey, 215774

REGRESSION TREE BASED MODEL FOR PREDICTING NON-RELAPSE MORTALITY IN AML PATIENTS ALLO-TRANSPLANTED IN FIRST COMPLETE REMISSION

EHA Learning Center, Anish Puliyayil, 215775

COMPARISON OF BUSULFAN/CYCLOPHOSPHAMIDE ALONE AND IN COMBINATION WITH THIOTEPA OR ANTI-THYMOCYTE GLOBULIN ON HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOME AMONG BETA-THALASSEMIA PATIENTS

EHA Learning Center, Saqib Ansari, 215776

MURINE MODELS FOR ESTABLISHING STEROID REFRACTORY GVHD

EHA Learning Center, Tomomi Toubai, 215790

LOW-DOSE INTERLEUKIN-2 RESTORING HUMAN REGULATORY T CELL FUNCTION IN VITRO AS A POTENTIAL APPLICATION FOR GVHD THERAPY AFTER TRANSPLANTATION

EHA Learning Center, Tzeon-Jye Chiou, 215791

HYPOFRACTIONATED TOTAL LYMPHOID IRRADIATION BY HELICAL TOMOTHERAPY AND HIGH DOSE CHEMOTHERAPY AS CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH RELAPSED/REFRACTORY LYMPHOMA

EHA Learning Center, Fabio Guolo, 215792

MUTATION SPECTRUM IN HBB, HBA1 AND HBA2 GENES IN PATIENTS FROM EUROPEAN PART OF RUSSIA

EHA Learning Center, Svetlana Mann, 215807

COMPREHENSIVE SCREENING FOR COEXISTING HETEROZYGOUS Α0-THALASSEMIA IN HEMOGLOBIN E TRAIT

EHA Learning Center, Piroonrut Wongprachar, 215808

ARE ALL DIRECT ORAL ANTICOAGULANTS EQUAL TO SAFETY AND EFFICACY?

EHA Learning Center, Begoña Navarro Almenzar, 215809

QUALITY CONTROL IN CRYOPRESERVED POOLED PLATELETS: 9-YEAR EXPERIENCE IN A TRANSFUSION CENTRE.

EHA Learning Center, Pablo Romero Garcia, 215823

BACTERIAL CONTAMINANTS AND BIOFILMS EFFECT PLATELET ACTIVATION AND FUNCTION: IMPLICATIONS IN PLATELET TRANSFUSIONS

EHA Learning Center, Joels Wilson-Nieuwenhuis, 215824

ALLOIMMUNIZATION TO D AND NON-D RHESUS ANTIGENS INDUCED BY PLATELET TRANSFUSIONS

EHA Learning Center, Michael Daskalakis, 215825

NIVOLUMAB TREATMENT DISCONTINUATION IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY EXPERIENCE

EHA Learning Center, Liudmila Fedorova, 215903

RELEVANCE OF PRE AND POST TRANSPLANT PET AND HASENCLEVER INDEX IN PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANT FOR HODGKIN LYMPHOMA

EHA Learning Center, Siddharth Turkar, 215904

A REAL WORLD STUDY OF CLINICAL CHARACTERISTICS AND TREATMENT OUTCOME OF HODGKIN LYMPHOMA IN MALAYSIA: A SINGLE CENTER EXPERIENCE IN A RESOURCE LIMITED SETTING

EHA Learning Center, Tze Shin Leong, 215905

ALLOGENEIC STEM CELL TRANSPLANTATION OVERCOMES THE NEGATIVE PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN TRANSPLANT ELIGIBLE PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA.

EHA Learning Center, Abhishek Mangaonkar, 215919

HEMATOLOGICAL PHENOTYPES OF DIFFERENT ALPHA-THALASSAEMIA GENOTYPES CAUSING HYPOCHROMIC MICROCYTIC ANEMIA AT NEONATAL PERIOD

EHA Learning Center, thidarat suksangpleng, 215920

INVOLVEMENT OF LEUCOCYTE DERIVED EXTRACELLULAR VESICLES IN THE PROCOAGULANT STATE FOUND IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA-RELATED CONDITION

EHA Learning Center, Adeline Wannez, 215921